ArticleJournal of translational medicine2026
Folate promotes colorectal cancer progression by impairing CD8
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- One-carbon metabolism in cancer immunity: T-cell fitness, epigenetic programming, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Post-Translational Modifications in Cancer-Associated CD8⁺ T-Cell Exhaustion: Mechanisms and Therapeutic Opportunities.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDietary factors have been recognised as contributors to the etiology of colorectal cancer (CRC). Folate is a micronutrient of critical importance to human health, frequently utilized as a dietary supplement. Previous clinical evidence suggested that folate intake is associated with an increased risk of CRC. However, the underlying mechanisms remain unclear. Here, we report that folate supplementation significantly promotes CRC growth and is associated with functional exhaustion of cytotoxic CD8
methodsUsing subcutaneous and orthotopic colorectal cancer mouse models, we investigated the impact of folate on CRC progression. Flow cytometry, immunohistochemistry, immunofluorescence, Transwell assays, RNA sequencing, and ChIP-qPCR were employed to elucidate the role and underlying mechanisms of folate in modulating CD8
resultsOur study indicates that folate directly impairs cytotoxic CD8
conclusionsThis preclinical study suggests that folate may facilitate CRC progression and immune evasion by impairing CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.